Cargando…
The potential effects and mechanisms of Gegen Qinlian Decoction in oxaliplatin-resistant colorectal cancer based on network pharmacology
BACKGROUND: Resistance to chemotherapeutic drugs, such as oxaliplatin (OXA), can lead to unsatisfactory chemotherapy results during the treatment of advanced colorectal cancer (CRC). Therefore, we investigated the potential targets and mechanisms of Gegen Qinlian Decoction (GQD) against OXA-resistan...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9638763/ https://www.ncbi.nlm.nih.gov/pubmed/36353164 http://dx.doi.org/10.1016/j.heliyon.2022.e11305 |
_version_ | 1784825495545708544 |
---|---|
author | Lin, Xiang Xu, Li Tan, Huicheng Zhang, Xinyi Shao, Huan Yao, Li Huang, Xuan |
author_facet | Lin, Xiang Xu, Li Tan, Huicheng Zhang, Xinyi Shao, Huan Yao, Li Huang, Xuan |
author_sort | Lin, Xiang |
collection | PubMed |
description | BACKGROUND: Resistance to chemotherapeutic drugs, such as oxaliplatin (OXA), can lead to unsatisfactory chemotherapy results during the treatment of advanced colorectal cancer (CRC). Therefore, we investigated the potential targets and mechanisms of Gegen Qinlian Decoction (GQD) against OXA-resistant CRC through network pharmacology and performed molecular docking and experimental verification. METHODS: We collected potential compounds, targets, and related disease genes from public databases. The pharmacology model of the compound-target-pathway network and protein-protein interaction (PPI) network were established. The potential active components and mechanisms underlying GQD reversing OXA-resistant CRC were systematically predicted, and the key targets were verified by performing molecular docking and in vitro and in vivo experiments. RESULTS: A total of 160 active ingredients, 407 potential targets, and 406 CRC drug resistance genes were collected. 16 intersecting genes, which included ABCG2 and belonged to 139 active compounds including baicalin and wogonin. They were enriched in 12 signaling pathways, including ABC transport and metabolism. Along with network topology analysis, ABCB1 and ABCC2 were identified as key targets and proved that various active components of GQD combined well with them. GQD alone and synergized with OXA could inhibit the protein and mRNA of ABC transporters in vivo and in vitro, decrease the IC(50) of OXA-resistant CRC to OXA with a good synergistic index at different treatment times and concentrations, improve the sensitivity of OXA-resistant CRC to OXA, inhibit drug efflux, decrease tumor volume, and increase the weight of nude mice at the late stage of treatment. CONCLUSIONS: GQD can target ATP-binding proteins, inhibit ABC transporters, reverse OXA resistance, increase the sensitivity of OXA-resistant CRC cells to OXA, decrease tumor volume, alleviate toxic side effects, improve prognosis, and have good synergistic therapeutic effects. These results provide an effective research tool to elucidate ethnomedicine for modernizing refractory diseases. |
format | Online Article Text |
id | pubmed-9638763 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-96387632022-11-08 The potential effects and mechanisms of Gegen Qinlian Decoction in oxaliplatin-resistant colorectal cancer based on network pharmacology Lin, Xiang Xu, Li Tan, Huicheng Zhang, Xinyi Shao, Huan Yao, Li Huang, Xuan Heliyon Research Article BACKGROUND: Resistance to chemotherapeutic drugs, such as oxaliplatin (OXA), can lead to unsatisfactory chemotherapy results during the treatment of advanced colorectal cancer (CRC). Therefore, we investigated the potential targets and mechanisms of Gegen Qinlian Decoction (GQD) against OXA-resistant CRC through network pharmacology and performed molecular docking and experimental verification. METHODS: We collected potential compounds, targets, and related disease genes from public databases. The pharmacology model of the compound-target-pathway network and protein-protein interaction (PPI) network were established. The potential active components and mechanisms underlying GQD reversing OXA-resistant CRC were systematically predicted, and the key targets were verified by performing molecular docking and in vitro and in vivo experiments. RESULTS: A total of 160 active ingredients, 407 potential targets, and 406 CRC drug resistance genes were collected. 16 intersecting genes, which included ABCG2 and belonged to 139 active compounds including baicalin and wogonin. They were enriched in 12 signaling pathways, including ABC transport and metabolism. Along with network topology analysis, ABCB1 and ABCC2 were identified as key targets and proved that various active components of GQD combined well with them. GQD alone and synergized with OXA could inhibit the protein and mRNA of ABC transporters in vivo and in vitro, decrease the IC(50) of OXA-resistant CRC to OXA with a good synergistic index at different treatment times and concentrations, improve the sensitivity of OXA-resistant CRC to OXA, inhibit drug efflux, decrease tumor volume, and increase the weight of nude mice at the late stage of treatment. CONCLUSIONS: GQD can target ATP-binding proteins, inhibit ABC transporters, reverse OXA resistance, increase the sensitivity of OXA-resistant CRC cells to OXA, decrease tumor volume, alleviate toxic side effects, improve prognosis, and have good synergistic therapeutic effects. These results provide an effective research tool to elucidate ethnomedicine for modernizing refractory diseases. Elsevier 2022-10-30 /pmc/articles/PMC9638763/ /pubmed/36353164 http://dx.doi.org/10.1016/j.heliyon.2022.e11305 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Research Article Lin, Xiang Xu, Li Tan, Huicheng Zhang, Xinyi Shao, Huan Yao, Li Huang, Xuan The potential effects and mechanisms of Gegen Qinlian Decoction in oxaliplatin-resistant colorectal cancer based on network pharmacology |
title | The potential effects and mechanisms of Gegen Qinlian Decoction in oxaliplatin-resistant colorectal cancer based on network pharmacology |
title_full | The potential effects and mechanisms of Gegen Qinlian Decoction in oxaliplatin-resistant colorectal cancer based on network pharmacology |
title_fullStr | The potential effects and mechanisms of Gegen Qinlian Decoction in oxaliplatin-resistant colorectal cancer based on network pharmacology |
title_full_unstemmed | The potential effects and mechanisms of Gegen Qinlian Decoction in oxaliplatin-resistant colorectal cancer based on network pharmacology |
title_short | The potential effects and mechanisms of Gegen Qinlian Decoction in oxaliplatin-resistant colorectal cancer based on network pharmacology |
title_sort | potential effects and mechanisms of gegen qinlian decoction in oxaliplatin-resistant colorectal cancer based on network pharmacology |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9638763/ https://www.ncbi.nlm.nih.gov/pubmed/36353164 http://dx.doi.org/10.1016/j.heliyon.2022.e11305 |
work_keys_str_mv | AT linxiang thepotentialeffectsandmechanismsofgegenqinliandecoctioninoxaliplatinresistantcolorectalcancerbasedonnetworkpharmacology AT xuli thepotentialeffectsandmechanismsofgegenqinliandecoctioninoxaliplatinresistantcolorectalcancerbasedonnetworkpharmacology AT tanhuicheng thepotentialeffectsandmechanismsofgegenqinliandecoctioninoxaliplatinresistantcolorectalcancerbasedonnetworkpharmacology AT zhangxinyi thepotentialeffectsandmechanismsofgegenqinliandecoctioninoxaliplatinresistantcolorectalcancerbasedonnetworkpharmacology AT shaohuan thepotentialeffectsandmechanismsofgegenqinliandecoctioninoxaliplatinresistantcolorectalcancerbasedonnetworkpharmacology AT yaoli thepotentialeffectsandmechanismsofgegenqinliandecoctioninoxaliplatinresistantcolorectalcancerbasedonnetworkpharmacology AT huangxuan thepotentialeffectsandmechanismsofgegenqinliandecoctioninoxaliplatinresistantcolorectalcancerbasedonnetworkpharmacology AT linxiang potentialeffectsandmechanismsofgegenqinliandecoctioninoxaliplatinresistantcolorectalcancerbasedonnetworkpharmacology AT xuli potentialeffectsandmechanismsofgegenqinliandecoctioninoxaliplatinresistantcolorectalcancerbasedonnetworkpharmacology AT tanhuicheng potentialeffectsandmechanismsofgegenqinliandecoctioninoxaliplatinresistantcolorectalcancerbasedonnetworkpharmacology AT zhangxinyi potentialeffectsandmechanismsofgegenqinliandecoctioninoxaliplatinresistantcolorectalcancerbasedonnetworkpharmacology AT shaohuan potentialeffectsandmechanismsofgegenqinliandecoctioninoxaliplatinresistantcolorectalcancerbasedonnetworkpharmacology AT yaoli potentialeffectsandmechanismsofgegenqinliandecoctioninoxaliplatinresistantcolorectalcancerbasedonnetworkpharmacology AT huangxuan potentialeffectsandmechanismsofgegenqinliandecoctioninoxaliplatinresistantcolorectalcancerbasedonnetworkpharmacology |